Dr. Reddy's Laboratories Limited (RDY)
USD 14.55
(0.48%)
USD 14.55
(0.48%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 | 20.02 Billion INR | 48.6% |
| 2023 | 13.47 Billion INR | -60.2% |
| 2022 | 33.84 Billion INR | 11.67% |
| 2021 | 30.3 Billion INR | 37.13% |
| 2020 | 22.1 Billion INR | -42.41% |
| 2019 | 38.38 Billion INR | -24.32% |
| 2018 | 50.71 Billion INR | 3.11% |
| 2017 | 49.18 Billion INR | 46.76% |
| 2016 | 33.51 Billion INR | -22.29% |
| 2015 | 43.12 Billion INR | -3.61% |
| 2014 | 44.74 Billion INR | -87.83% |
| 2013 | 367.59 Billion INR | 1041.25% |
| 2012 | 32.21 Billion INR | 36.38% |
| 2011 | 23.61 Billion INR | 60.71% |
| 2010 | 14.69 Billion INR | -25.41% |
| 2009 | 19.7 Billion INR | 0.82% |
| 2008 | 19.54 Billion INR | -21.24% |
| 2007 | 24.81 Billion INR | -20.15% |
| 2006 | 31.07 Billion INR | 999.07% |
| 2005 | 2.82 Billion INR | 459.42% |
| 2004 | 505.42 Million INR | 53.11% |
| 2003 | 330.09 Million INR | 116.3% |
| 2002 | 152.61 Million INR | -96.12% |
| 2001 | 3.93 Billion INR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 12.52 Billion INR | -7.07% |
| 2024 Q3 | 19.85 Billion INR | 50.05% |
| 2024 FY | 20.02 Billion INR | 48.6% |
| 2024 Q4 | 20.02 Billion INR | 0.85% |
| 2024 Q2 | 13.23 Billion INR | 5.67% |
| 2023 Q3 | 17.66 Billion INR | 2.16% |
| 2023 Q1 | 24.66 Billion INR | -27.12% |
| 2023 FY | 13.47 Billion INR | -60.2% |
| 2023 Q4 | 13.47 Billion INR | -23.73% |
| 2023 Q2 | 17.28 Billion INR | -29.91% |
| 2022 Q1 | 33.37 Billion INR | 10.11% |
| 2022 FY | 33.84 Billion INR | 11.67% |
| 2022 Q2 | 30.27 Billion INR | -9.29% |
| 2022 Q4 | 33.84 Billion INR | 20.17% |
| 2022 Q3 | 28.16 Billion INR | -6.97% |
| 2021 Q2 | 27.42 Billion INR | -13.15% |
| 2021 FY | 30.3 Billion INR | 37.13% |
| 2021 Q1 | 31.58 Billion INR | 42.89% |
| 2021 Q4 | 30.3 Billion INR | 48.26% |
| 2021 Q3 | 20.44 Billion INR | -25.47% |
| 2020 Q1 | 34.38 Billion INR | -10.4% |
| 2020 FY | 22.1 Billion INR | -42.41% |
| 2020 Q4 | 22.1 Billion INR | 35.43% |
| 2020 Q3 | 16.32 Billion INR | -48.26% |
| 2020 Q2 | 31.54 Billion INR | -8.27% |
| 2019 Q3 | 43.83 Billion INR | -21.05% |
| 2019 FY | 38.38 Billion INR | -24.32% |
| 2019 Q1 | 54.27 Billion INR | 7.02% |
| 2019 Q2 | 55.52 Billion INR | 2.3% |
| 2019 Q4 | 38.38 Billion INR | -12.44% |
| 2018 Q3 | 54.91 Billion INR | 2.32% |
| 2018 FY | 50.71 Billion INR | 3.11% |
| 2018 Q1 | 50.46 Billion INR | 2.6% |
| 2018 Q2 | 53.66 Billion INR | 6.35% |
| 2018 Q4 | 50.71 Billion INR | -7.64% |
| 2017 FY | 49.18 Billion INR | 46.76% |
| 2017 Q4 | 49.18 Billion INR | -15.2% |
| 2017 Q3 | 57.99 Billion INR | -4.1% |
| 2017 Q2 | 60.48 Billion INR | 60.71% |
| 2017 Q1 | 37.63 Billion INR | 12.29% |
| 2016 Q4 | 33.51 Billion INR | -0.85% |
| 2016 FY | 33.51 Billion INR | -22.29% |
| 2016 Q2 | 37.07 Billion INR | -10.45% |
| 2016 Q3 | 33.8 Billion INR | -8.83% |
| 2016 Q1 | 41.4 Billion INR | -4.0% |
| 2015 Q3 | 39.65 Billion INR | 2.06% |
| 2015 Q2 | 38.85 Billion INR | -7.09% |
| 2015 Q4 | 43.12 Billion INR | 8.75% |
| 2015 Q1 | 41.81 Billion INR | -6.54% |
| 2015 FY | 43.12 Billion INR | -3.61% |
| 2014 FY | 44.74 Billion INR | -87.83% |
| 2014 Q1 | 43.99 Billion INR | -88.03% |
| 2014 Q2 | 49.22 Billion INR | 11.89% |
| 2014 Q3 | 49.34 Billion INR | 0.25% |
| 2014 Q4 | 44.74 Billion INR | -9.33% |
| 2013 Q2 | 34.9 Billion INR | -1.49% |
| 2013 FY | 367.59 Billion INR | 1041.25% |
| 2013 Q4 | 367.59 Billion INR | 898.23% |
| 2013 Q3 | 36.82 Billion INR | 5.51% |
| 2013 Q1 | 35.43 Billion INR | 10.0% |
| 2012 Q3 | 38.5 Billion INR | 23.0% |
| 2012 Q1 | 23.94 Billion INR | 1.37% |
| 2012 FY | 32.21 Billion INR | 36.38% |
| 2012 Q4 | 32.21 Billion INR | -16.34% |
| 2012 Q2 | 31.3 Billion INR | 30.76% |
| 2011 Q2 | 14.49 Billion INR | 4.48% |
| 2011 FY | 23.61 Billion INR | 60.71% |
| 2011 Q1 | 13.87 Billion INR | -5.6% |
| 2011 Q4 | 23.61 Billion INR | 71.04% |
| 2011 Q3 | 13.8 Billion INR | -4.73% |
| 2010 Q4 | 14.69 Billion INR | 15.96% |
| 2010 Q1 | 16.1 Billion INR | -18.24% |
| 2010 Q2 | 14.66 Billion INR | -8.94% |
| 2010 Q3 | 12.67 Billion INR | -13.6% |
| 2010 FY | 14.69 Billion INR | -25.41% |
| 2009 Q1 | 18.85 Billion INR | -3.53% |
| 2009 Q2 | 22.18 Billion INR | 17.71% |
| 2009 FY | 19.7 Billion INR | 0.82% |
| 2009 Q4 | 19.7 Billion INR | -11.51% |
| 2009 Q3 | 22.26 Billion INR | 0.34% |
| 2008 Q3 | 17.08 Billion INR | 4.71% |
| 2008 Q2 | 16.31 Billion INR | 6.54% |
| 2008 Q1 | 15.31 Billion INR | -38.27% |
| 2008 FY | 19.54 Billion INR | -21.24% |
| 2008 Q4 | 19.54 Billion INR | 14.36% |
| 2007 Q2 | 32.25 Billion INR | -3.29% |
| 2007 Q3 | 27.93 Billion INR | -13.39% |
| 2007 Q4 | 24.81 Billion INR | -11.16% |
| 2007 FY | 24.81 Billion INR | -20.15% |
| 2007 Q1 | 33.34 Billion INR | 7.31% |
| 2006 Q1 | 3.94 Billion INR | 39.61% |
| 2006 Q3 | 3.85 Billion INR | -6.77% |
| 2006 Q2 | 4.13 Billion INR | 4.83% |
| 2006 Q4 | 31.07 Billion INR | 705.49% |
| 2006 FY | 31.07 Billion INR | 999.07% |
| 2005 Q1 | 2.37 Billion INR | 369.66% |
| 2005 FY | 2.82 Billion INR | 459.42% |
| 2005 Q2 | 1.46 Billion INR | -38.23% |
| 2005 Q3 | 2.04 Billion INR | 39.51% |
| 2005 Q4 | 2.82 Billion INR | 38.22% |
| 2004 Q3 | 186.16 Million INR | 3.35% |
| 2004 Q4 | 505.42 Million INR | 171.49% |
| 2004 Q2 | 180.13 Million INR | -0.9% |
| 2004 FY | 505.42 Million INR | 53.11% |
| 2004 Q1 | 181.76 Million INR | -44.93% |
| 2003 FY | 330.09 Million INR | 116.3% |
| 2003 Q2 | 189.85 Million INR | 4.5% |
| 2003 Q1 | 181.68 Million INR | 19.05% |
| 2003 Q4 | 330.09 Million INR | 73.32% |
| 2003 Q3 | 190.45 Million INR | 0.32% |
| 2002 Q1 | 529.46 Million INR | 0.0% |
| 2002 FY | 152.61 Million INR | -96.12% |
| 2002 Q2 | 363.22 Million INR | -31.4% |
| 2002 Q3 | 198.07 Million INR | -45.47% |
| 2002 Q4 | 152.61 Million INR | -22.95% |
| 2001 FY | 3.93 Billion INR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Amneal Pharmaceuticals, Inc. | 2.75 Billion USD | -627.862% |
| Bausch Health Companies Inc. | 22.38 Billion USD | 10.577% |
| Catalent, Inc. | 4.98 Billion USD | -301.363% |
| Emergent BioSolutions Inc. | 877.5 Million USD | -2181.481% |
| Elanco Animal Health Incorporated | 5.77 Billion USD | -246.727% |
| Perrigo Company plc | 4.07 Billion USD | -391.481% |
| Teva Pharmaceutical Industries Limited | 20.15 Billion USD | 0.66% |
| Zoetis Inc. | 6.8 Billion USD | -194.282% |